

# Gretchen L Sacha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2428254/publications.pdf>

Version: 2024-02-01

52  
papers

618  
citations

623734

14  
h-index

642732

23  
g-index

52  
all docs

52  
docs citations

52  
times ranked

728  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Utilization of Stress Dose Hydrocortisone in Adult Patients With Septic Shock: A Retrospective Observational Study at a Large Academic Medical Center. <i>Journal of Pharmacy Practice</i> , 2023, 36, 606-613.	1.0	1
2	Hemodynamic Response to Vasopressin Dosage of 0.03 Units/Min vs. 0.04 Units/Min in Patients With Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 92-99.	2.8	5
3	Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock*. <i>Critical Care Medicine</i> , 2022, 50, 614-623.	0.9	56
4	Association Between Vasopressin Rebranding and Utilization in Patients With Septic Shock*. <i>Critical Care Medicine</i> , 2022, 50, 644-654.	0.9	13
5	Association of Arterial pH With Hemodynamic Response to Vasopressin in Patients With Septic Shock: An Observational Cohort Study. , 2022, 4, e0634.		9
6	Determinants of Vancomycin Trough Concentration in Patients Receiving Continuous Veno-Venous Hemodialysis. <i>Annals of Pharmacotherapy</i> , 2022, 56, 1133-1138.	1.9	2
7	Timing of vasoactive agents and corticosteroid initiation in septic shock. <i>Annals of Intensive Care</i> , 2022, 12, .	4.6	23
8	Evaluation of the Initiation Timing of Hydrocortisone in Adult Patients With Septic Shock. <i>Shock</i> , 2021, 55, 488-494.	2.1	10
9	System-Wide Strategies Were Associated With Improved Outcome in Critically Ill Patients With Coronavirus Disease 2019. <i>Chest</i> , 2021, 159, 1072-1075.	0.8	5
10	Effect of Phenylephrine Push Before Continuous Infusion Norepinephrine in Patients With Septic Shock. <i>Chest</i> , 2021, 159, 1875-1883.	0.8	13
11	Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 157-174.	2.8	68
12	Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis. , 2021, 3, e0327.		12
13	Author's Response: Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock. <i>Shock</i> , 2021, 56, 870.	2.1	0
14	Update to coagulopathy in COVID-19: Manifestations and management. <i>Cleveland Clinic Journal of Medicine</i> , 2021, , .	1.3	7
15	Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock. <i>Shock</i> , 2021, 55, 210-214.	2.1	8
16	Vasopressin Plasma Concentrations Are Not Associated with Hemodynamic Response to Exogenous Vasopressin for Septic Shock. <i>Pharmacotherapy</i> , 2020, 40, 33-39.	2.6	15
17	Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series Analysis. <i>Annals of Pharmacotherapy</i> , 2020, 54, 314-321.	1.9	9
18	31: HEMODYNAMIC RESPONSE TO INITIAL VASOPRESSIN DOSE OF 0.03 VERSUS 0.04 UNITS/MIN IN SEPTIC SHOCK. <i>Critical Care Medicine</i> , 2020, 48, 16-16.	0.9	0

#	ARTICLE	IF	CITATIONS
19	1672: EFFECT OF HYDROCORTISONE ON VASOPRESSOR DURATION IN PATIENTS WITH SEPTIC SHOCK. Critical Care Medicine, 2020, 48, 811-811.	0.9	0
20	1659: ABRUPT DISCONTINUATION VERSUS DOWN-TITRATION OF VASOPRESSIN IN PATIENTS RECOVERING FROM SEPTIC SHOCK. Critical Care Medicine, 2020, 48, 805-805.	0.9	5
21	28: EFFECT OF LACTATE, CATECHOLAMINE DOSE, AND TIMING IN PATIENTS WITH SEPTIC SHOCK ON VASOPRESSIN. Critical Care Medicine, 2020, 48, 14-14.	0.9	0
22	Coagulopathy in COVID-19: Manifestations and management. Cleveland Clinic Journal of Medicine, 2020, 87, 461-468.	1.3	68
23	Antivirals for COVID-19. Cleveland Clinic Journal of Medicine, 2020, , .	1.3	26
24	1598: ANALYSIS OF TAPERING VERSUS NO TAPERING OF STRESS-DOSE HYDROCORTISONE IN SEPTIC SHOCK. Critical Care Medicine, 2020, 48, 775-775.	0.9	1
25	1366: IMPLEMENTATION OF A PERIPHERAL NOREPINEPHRINE PROTOCOL IN A MEDICAL INTENSIVE CARE UNIT. Critical Care Medicine, 2020, 48, 660-660.	0.9	0
26	Comparison of Single-Dose and Extended-Duration Empiric Aminoglycoside Combination Therapy in Patients With Septic Shock. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.9	0
27	Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 257-267.	1.0	10
28	Optimal norepinephrine-equivalent dose to initiate epinephrine in patients with septic shock. Journal of Critical Care, 2019, 53, 69-74.	2.2	4
29	Effects of Norepinephrine and Vasopressin Discontinuation Order in the Recovery Phase of Septic Shock: A Systematic Review and Individual Patient Data Meta-Analysis. Pharmacotherapy, 2019, 39, 544-552.	2.6	19
30	1640: EFFECT OF PHENYLEPHRINE PUSHES PRIOR TO CONTINUOUS NOREPINEPHRINE IN PATIENTS WITH SEPTIC SHOCK. Critical Care Medicine, 2019, 47, 794-794.	0.9	0
31	32: DISCONTINUATION ORDER OF NE VS. AVP DURING SEPTIC SHOCK RECOVERY: SYSTEMATIC REVIEW & META-ANALYSIS. Critical Care Medicine, 2019, 47, 16-16.	0.9	0
32	1575: EFFECT OF A VASOPRESSIN RESTRICTION ALGORITHM ON PATIENT MORTALITY. Critical Care Medicine, 2019, 47, 763-763.	0.9	0
33	1583. Critical Care Medicine, 2019, 47, 767.	0.9	0
34	Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations. Pharmacotherapy, 2019, 39, 369-381.	2.6	19
35	Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock. Pharmacotherapy, 2018, 38, 319-326.	2.6	24
36	1507: OPTIMAL NOREPINEPHRINE-EQUIVALENT DOSE TO INITIATE EPINEPHRINE IN PATIENTS WITH SEPTIC SHOCK. Critical Care Medicine, 2018, 46, 737-737.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Body Mass's Impact on Response to Fixed-Dose Vasopressin in Patients With Septic Shock. Shock, 2018, 50, 388-394.	2.1	7
38	1420: IMPACT OF A VASOPRESSIN RESTRICTION GUIDELINE FOR PATIENTS WITH SEPTIC SHOCK. Critical Care Medicine, 2018, 46, 694-694.	0.9	0
39	1398: EFFECT OF BASELINE PH ON VASOPRESSIN RESPONSE IN PATIENTS WITH SEPTIC SHOCK. Critical Care Medicine, 2018, 46, 683-683.	0.9	1
40	1401: THE GOLDBLOCKS ZONE: VASOPRESSIN RESPONSE IS DEPENDENT ON ADMISSION LACTATE AND TIMING OF INITIATION. Critical Care Medicine, 2018, 46, 684-684.	0.9	28
41	1445: BODY MASS DOES NOT IMPACT RESPONSE TO FIXED-DOSE VASOPRESSIN IN PATIENTS WITH SEPTIC SHOCK. Critical Care Medicine, 2018, 46, 706-706.	0.9	0
42	Predictors of response to fixed-dose vasopressin in adult patients with septic shock. Annals of Intensive Care, 2018, 8, 35.	4.6	71
43	Safe Use of Vasopressin and Angiotensin <sc>II</sc> for Patients with Circulatory Shock. Pharmacotherapy, 2018, 38, 851-861.	2.6	18
44	Vasodilatory shock in the ICU and the role of angiotensin II. Current Opinion in Critical Care, 2018, 24, 277-285.	3.2	13
45	Retrospective Evaluation of the Use of Ceftolozane/Tazobactam at a Large Academic Medical Center. Infectious Diseases in Clinical Practice, 2017, 25, 305-309.	0.3	6
46	The Use of Gabapentin for Pain and Agitation in Neonates and Infants in a Neonatal ICU. Journal of Pediatric Pharmacology and Therapeutics, 2017, 22, 207-211.	0.5	21
47	Clinical Experience With Ceftolozane/Tazobactam at a Large Academic Medical Center. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
48	1355: PREDICTORS OF RESPONSE TO FIXED-DOSE VASOPRESSIN IN ADULT PATIENTS WITH SEPTIC SHOCK. Critical Care Medicine, 2016, 44, 414-414.	0.9	1
49	1360: HYPOTENSION RISK BASED ON VASOACTIVE DISCONTINUATION ORDER IN THE RECOVERY PHASE OF SEPTIC SHOCK. Critical Care Medicine, 2016, 44, 415-415.	0.9	0
50	1369: SEQUENTIAL ANALYSIS OF THE USE OF VASOPRESSIN AND CORTICOSTEROIDS IN PATIENTS WITH SEPTIC SHOCK. Critical Care Medicine, 2016, 44, 418-418.	0.9	0
51	The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center. Journal of Thrombosis and Thrombolysis, 2016, 42, 479-485.	2.1	14
52	Did the beneficial renal outcomes with vasopressin VANISH?. Annals of Translational Medicine, 2016, 4, S67-S67.	1.7	4